Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2015 05/21/2015 05/22/2015 05/26/2015 05/27/2015 Date
127.97(c) 126.88(c) 127.19(c) 127.11(c) 129.54 Last
1 066 260 874 659 773 547 1 047 704 1 718 399 Volume
+2.38% -0.85% +0.24% -0.06% +1.91% Change
More quotes
Financials ($)
Sales 2015 882 M
EBIT 2015 -309 M
Net income 2015 -340 M
Finance 2015 82,6 M
Yield 2015 -
Sales 2016 1 103 M
EBIT 2016 -198 M
Net income 2016 -255 M
Debt 2016 257 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 23,0x
EV / Sales 2016 18,7x
Capitalization 20 380 M
More Financials
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.The company operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
06/09Shareholder meeting
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
09:55aDJRetrophin Sells FDA Voucher to Sanofi
05/06DJAlexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update
05/06 BIOMARIN PHARMACEUTICAL : Reports Outline Phenylketonurias Study Results from Bi..
05/02 BioMarin Announces First Quarter 2015 Financial Results and Company Update
05/01 BIOMARIN PHARMACEUTICAL : Management to Present at the Deutsche Bank 40th Annual..
04/30 BIOMARIN PHARMACEUTICAL : reports 1Q loss
04/30 BIOMARIN PHARMACEUTICAL : Results of Operations and Financial Condition, Financi..
04/30 BioMarin Announces First Quarter 2015 Financial Results and Company Update
More news
Sector news : Generic Pharmaceuticals
07:35p TAKEDA PHARMACEUTICAL : ZAFATEK® Now Available for the Treatment of Type 2 Diabe..
05:59p VALEANT PHARMACEUTICALS INTL : Salix Announces FDA Approval of Xifaxan® 550 mg f..
05:59p VALEANT PHARMACEUTICALS INTL : Salix Announces FDA Approval of Xifaxan® 550 mg f..
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
05:41p After Hours Gainers / Losers
05/23 UPCOMING EVENTS : A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's ..
05/19 Sarepta to initiate rolling NDA submission for eteplirsen
05/18 CarMax Is Extraordinarily Strong - Cramer's Lightning Round (5/15/15)
05/07 Alexion Puts Its Stock To Use At Last


Comments 
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions